Retatrutide + Tesamorelin Blend

Retatrutide + Tesamorelin Blend Research Material — Buy Retatrutide / Tesamorelin (≥97% Purity)

This blend combines Retatrutide, a unimolecular triple agonist of the GIP, GLP-1, and glucagon receptors, with Tesamorelin, a stabilized GHRH(1-44) analog. The two compounds act on distinct hormonal axes — incretin/glucagon metabolic signaling and the growth hormone/IGF-1 axis — that are studied together for combined effects on metabolic and somatotropic research models.

Mechanism of Action

Retatrutide engages the GIP, GLP-1, and glucagon receptors simultaneously, combining GLP-1-mediated appetite suppression and insulinotropic signaling, GIP-mediated insulin sensitization, and glucagon-receptor-driven increases in energy expenditure and lipolysis. Tesamorelin binds the GHRH receptor on pituitary somatotrophs, stimulating Gs-coupled cAMP/PKA signaling and growth hormone release, elevating downstream IGF-1, with a stabilized structure that resists enzymatic degradation relative to native GHRH.

Research Applications

• Combined incretin/glucagon and GHRH-receptor secretagogue research
• Metabolic rate, energy expenditure, and body-composition research models
• IGF-1 axis and hepatic signaling studies
• Comparative multi-pathway metabolic/somatotropic combination studies

Specifications

• Components: Retatrutide + Tesamorelin
• CAS Numbers: Retatrutide 2381272-15-5; Tesamorelin 218949-48-5
• Purity: ≥97% (HPLC verified, each component)
• Form: Lyophilized powder blend
• Available Size: 10mg / 10mg (Retatrutide / Tesamorelin)

Storage & Handling

Store lyophilized blend at −20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 4°C and use within 28 days. All handling should be performed under sterile laboratory conditions by trained research personnel.

For in-vitro laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or medicinal product.